US EditionSanofi’s Neuro Pipeline Expands to Alzheimer’s With $470M Vigil Neuroscience Acquisition
- Sanofi has agreed to acquire the US-based clinical-stage company Vigil Neuroscience for $470 million in cash to strengthen its neurology portfolio with a potential new treatment for Alzheimer's disease.
- Last year, Sanofi invested $40 million in Vigil, securing rights to VG-3927, an oral TREM2-targeting drug currently undergoing Phase 1 trials.
- VG-3927 safely stimulates TREM2 receptors on brain microglia, which are linked to neurodegeneration, and Vigil plans a Phase 2 trial in Q3 2025.
- The offer price of $8 per share represents a 246% premium over Vigil’s recent stock price, with an additional $2 per share contingent on VG-3927’s commercial launch.
- The acquisition expands Sanofi’s neurology focus, transferring VG-101 rights back to Amgen, and may provide a new treatment approach amid limited Alzheimer’s options.
12 Articles
12 Articles
Sanofi’s Neuro Pipeline Expands to Alzheimer’s With $470M Vigil Neuroscience Acquisition
The Alzheimer’s disease drugs that have reached the market in the past two years are antibodies designed to break up amyloid plaques. Vigil Neuroscience brings to Sanofi a different approach: an oral small molecule designed to activate microglia, immune cells that play a key role in brain health. The post Sanofi’s Neuro Pipeline Expands to Alzheimer’s With $470M Vigil Neuroscience Acquisition appeared first on MedCity News.
DECRYPTAGE - The potential market is considerable. 35 million people worldwide are affected by the disease, and this figure is expected to increase sharply in the coming years.
Sanofi Acquires Vigil Neuroscience in $470 Million Deal to Bolster Alzheimer’s Drug Pipeline - Channelchek
Key Points:– Sanofi to acquire Vigil Neuroscience for $470 million, expanding its neurology focus.– Deal includes $8 per share and a $2 contingent value right tied to an Alzheimer’s candidate.– The acquisition strengthens Sanofi’s long-term R&D pipeline without impacting 2025 guidance. In a strategic move to deepen its commitment to neuroscience and neurodegenerative disorders, French pharmaceutical giant Sanofi (SASY.PA) announced it will acqui…
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
